Tryp Identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.
Tryptamine Therapeutics has raised $4.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2024.
Tryptamine Therapeutics's investors include Marc Lustig, Jason Carroll.
Tryptamine Therapeutics is headquartered in Kelowna, Canada.
Tryp Identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.
Tryptamine Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tryptamine Therapeutics — Funding & Investors." VCBacked, May 1, 2024, https://www.vcbacked.co/company/tryptamine-therapeutics. Accessed August 13, 2026.
VCBacked. (2024). Tryptamine Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/tryptamine-therapeutics
{{cite web |title=Tryptamine Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tryptamine-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated